Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Germolene antiseptic ointment
131005000BBAVA0
|
Proprietary compound preparation BNF 1310050 | Other minor cut and abrasion preparations | Skin | No data available |
|
Germoloids Suppositories & Ointment Duo Pack
0107010N0BFADAI
|
Germoloids | Lidocaine hydrochloride | Gastro-Intestinal System | No data available |
|
Gestone 100mg/2ml solution for injection ampoules
0604012S0BCADAH
|
Gestone | Progesterone | Endocrine System | No data available |
|
Gestone 25mg/1ml solution for injection ampoules
0604012S0BCABAC
|
Gestone | Progesterone | Endocrine System | No data available |
|
Gestone 50mg/1ml solution for injection ampoules
0604012S0BCACAD
|
Gestone | Progesterone | Endocrine System | No data available |
|
Gestonorone 200mg/2ml solution for injection ampoules
0803020D0AAAAAA
|
Gestonorone hexanoate | Gestonorone hexanoate | Malignant Disease and Immunosuppression | No data available |
|
Gestrinone 2.5mg capsules
0607020F0AAAAAA
|
Gestrinone | Gestrinone | Endocrine System | No data available |
|
GHRH Ferring 50microgram inj ampoules
0605010ACBBAAAA
|
GHRH Ferring | Somatorelin | Endocrine System | No data available |
|
Gielism 60mg capsules
0102000A0BEAAAA
|
Gielism | Alverine citrate | Gastro-Intestinal System | No data available |
|
Gilenya 0.25mg capsules
0802040ADBBABAB
|
Gilenya | Fingolimod | Malignant Disease and Immunosuppression | No data available |
|
Gilenya 0.5mg capsules
0802040ADBBAAAA
|
Gilenya | Fingolimod | Malignant Disease and Immunosuppression | No data available |
|
Gilotrif 20mg tablets
0801050BPBBACAC
|
Gilotrif | Afatinib | Malignant Disease and Immunosuppression | No data available |
|
Gilotrif 30mg tablets
0801050BPBBAAAA
|
Gilotrif | Afatinib | Malignant Disease and Immunosuppression | No data available |
|
Gilotrif 40mg tablets
0801050BPBBABAB
|
Gilotrif | Afatinib | Malignant Disease and Immunosuppression | No data available |
|
Gilteritinib 40mg tablets
0801030AGAAAAAA
|
Gilteritinib | Gilteritinib | Malignant Disease and Immunosuppression | No data available |
|
Ginger root tincture
190606000BCVUA0
|
Proprietary compound preparation BNF 1906060 | Other tincture preparations | Other Drugs and Preparations | No data available |
|
Ginger syrup
190607000AAAGAG
|
Generic compound preparation BNF 1906070 | Other syrup preparations | Other Drugs and Preparations | No data available |
|
Ginger tincture strong
190606000AAALAL
|
Generic compound preparation BNF 1906060 | Other tincture preparations | Other Drugs and Preparations | No data available |
|
Ginkyo 120mg tablets
091200000BEANA0
|
Proprietary compound preparation BNF 0912000 | Other health supplement preparations | Nutrition and Blood | No data available |
|
Ginkyo 50mg tablets
091200000BCTZA0
|
Proprietary compound preparation BNF 0912000 | Other health supplement preparations | Nutrition and Blood | No data available |
|
Ginseng 600mg capsules
091200000AAFHFH
|
Generic compound preparation BNF 0912000 | Other health supplement preparations | Nutrition and Blood | No data available |
|
Ginseng root tincture
190606000BCVZA0
|
Proprietary compound preparation BNF 1906060 | Other tincture preparations | Other Drugs and Preparations | No data available |
|
Giotrif 20mg tablets
0801050BPBCAAAC
|
Giotrif | Afatinib | Malignant Disease and Immunosuppression | No data available |
|
Giotrif 30mg tablets
0801050BPBCABAA
|
Giotrif | Afatinib | Malignant Disease and Immunosuppression | No data available |
|
Giotrif 40mg tablets
0801050BPBCACAB
|
Giotrif | Afatinib | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.